Trial Review

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements. New passwords must include at least one lowercase letter, one uppercase letter, one number and one special character (e.g. !#$%&@).
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621000791831
Ethics application status
Approved
Date submitted
13/04/2021
Date registered
23/06/2021
Date last updated
30/05/2023
Date data sharing statement initially provided
23/06/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Percutaneous Decannulation of Extracorporeal Membrane Oxygenation Using MANTA Vascular Closure Device
Scientific title
Feasibility of Percutaneous Decannulation of Extracorporeal Membrane Oxygenation Using MANTA Vascular Closure Device in Adults
Secondary ID [1] 303896 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Extracorporeal Membrane Oxygenation 321474 0
Condition category
Condition code
Cardiovascular 319235 319235 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Following VA-ECMO decannulation, the MANTA Vascular Closure Device will be used for percutaneous closure of the large bore arterial cannula site (as opposed to open surgery). The percutaneous closure will be performed by an interventional cardiologist in the cardiac catheter laboratory with an intensive care specialist and cardiothoracic or vascular surgeon on standby. The intervention will be delivered once. A Teleflex Medical (device manufacturer) representative will be available to the interventional team to ensure that the device is used in keeping with manufacturer specifics.
Intervention code [1] 320200 0
Treatment: Devices
Comparator / control treatment
No control (single arm feasibility study)
Control group
Uncontrolled

Outcomes
Primary outcome [1] 327104 0
Puncture closure without the use of surgical or additional endovascular intervention Assessment: Trial team notification by the multidisciplinary medical team, patient medical records.
Timepoint [1] 327104 0
72 hours
Secondary outcome [1] 393797 0
Access site or access-related vascular injury (dissection, stenosis, perforation, rupture, AV fistula, pseudoaneurysm, haematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) Assessment: Trial team notification by the multidisciplinary medical team, investigations as per the standard of care (if conducted by the treating team), patient medical records.
Timepoint [1] 393797 0
30 days
Secondary outcome [2] 393798 0
Distal embolization requiring surgery or resulting in amputation or irreversible end-organ damage Assessment: Trial team notification by the multidisciplinary medical team, patient medical records.
Timepoint [2] 393798 0
30 days
Secondary outcome [3] 393799 0
Unplanned endovascular or surgical intervention associated with death, major bleeding, visceral ischaemia or neurological impairment Assessment: Trial team notification by the multidisciplinary medical team, patient medical records.
Timepoint [3] 393799 0
30 days
Secondary outcome [4] 393800 0
Any new ipsilateral lower extremity ischaemia Assessment: Trial team notification by the multidisciplinary medical team, patient medical records.
Timepoint [4] 393800 0
30 days
Secondary outcome [5] 393801 0
Surgery for access site-related nerve injury or permanent access site related nerve injury Assessment: Trial team notification by the multidisciplinary medical team, patient medical records.
Timepoint [5] 393801 0
30 days
Secondary outcome [6] 393802 0
Life threatening or disabling bleeding (BARC 3b, 3c, 5) Assessment: Trial team notification by the multidisciplinary medical team, investigations as per the standard of care (if conducted by the treating team), patient medical records.
Timepoint [6] 393802 0
30 days
Secondary outcome [7] 393803 0
Major bleeding (BARC 3a) Assessment: Trial team notification by the multidisciplinary medical team, investigations as per the standard of care (if conducted by the treating team), patient medical records.
Timepoint [7] 393803 0
30 days
Secondary outcome [8] 393804 0
Access site related infection requiring intravenous antibiotics Assessment: Trial team notification by the multidisciplinary medical team, investigations as per the standard of care (if conducted by the treating team), patient medical records.
Timepoint [8] 393804 0
30 days

Eligibility
Key inclusion criteria
- Deemed appropriate by the multi-disciplinary team discussion including ICU physician, cardiothoracic surgeon, vascular surgeon, and interventional cardiologist.
- Suitable vascular anatomy as established by vascular ultrasound.
- Suitable body habitus (body mass index >20kg/m2 and <40 kg/m2).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Non femoral ECMO.
- Thrombus in CFA/SFA .
- Track depth on ultrasound exceeding 7cm.
- Puncture site of arterial cannula close to bifurcation , or other unfavourable features such as heavily calcified CFA.
- Arterial re-cannulation cases.
- ECMO > 14 days in situ.
- Known bleeding disorder including thrombocytopenia (platelet count <50 000 cells/µL), thrombasthenia, haemophilia, von Willebrand disease.
- Cannula site infection.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
As this is a pilot study, only descriptive statistics will be used. Normally distributed continuous data will be expressed as mean (± SD). Non-normally distributed data will be expressed in median (range). Categorical variables will be expressed as number (percentage).

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
1/06/2022
Actual
1/11/2022
Date of last participant enrolment
Anticipated
1/06/2023
Actual
Date of last data collection
Anticipated
30/06/2023
Actual
Sample size
Target
20
Accrual to date
5
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 19064 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 33614 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 308284 0
Commercial sector/Industry
Name [1] 308284 0
Teleflex Medical Australia
Country [1] 308284 0
Australia
Primary sponsor type
Individual
Name
Antony Walton
Address
Department of Cardiology
Alfred Hospital
Heart Centre, Level 3 Phillip Block, 55 Commercial Road, Melbourne, VIC, 3004
Country
Australia
Secondary sponsor category [1] 309088 0
Individual
Name [1] 309088 0
Vincent Pellegrino
Address [1] 309088 0
Intensive Care Unit Alfred Hospital 55 Commercial Road, Melbourne, VIC, 3004
Country [1] 309088 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 308258 0
Alfred HREC
Ethics committee address [1] 308258 0
Ethics committee country [1] 308258 0
Australia
Date submitted for ethics approval [1] 308258 0
26/04/2021
Approval date [1] 308258 0
27/05/2021
Ethics approval number [1] 308258 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 110106 0
A/Prof Antony Walton
Address 110106 0
Department of Cardiology Alfred Health Heart Centre, Level 3 Phillip Block, 55 Commercial Road, Melbourne, VIC, 3004
Country 110106 0
Australia
Phone 110106 0
+61 3 9426 6693
Fax 110106 0
Email 110106 0
[email protected]
Contact person for public queries
Name 110107 0
Antony Walton
Address 110107 0
Department of Cardiology Alfred Health Heart Centre, Level 3 Phillip Block, 55 Commercial Road, Melbourne, VIC, 3004
Country 110107 0
Australia
Phone 110107 0
+61 3 9426 6693
Fax 110107 0
Email 110107 0
[email protected]
Contact person for scientific queries
Name 110108 0
Antony Walton
Address 110108 0
Department of Cardiology Alfred Health Heart Centre, Level 3 Phillip Block, 55 Commercial Road, Melbourne, VIC, 3004
Country 110108 0
Australia
Phone 110108 0
+61 3 9426 6693
Fax 110108 0
Email 110108 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.